<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>10(20)</volume><submitter>Guckel D</submitter><pubmed_abstract>Remote magnetic navigation (RMN) facilitates ventricular arrhythmia (VA) ablation. This study aimed to evaluate the long-term efficacy of RMN-guided ablation for ventricular tachycardia (VT) and premature ventricular contractions (PVC). A total of 176 consecutive patients (mean age 53.23 ± 17.55 years, 37% female) underwent VA ablation for PVC (132 patients, 75%) or VT (44 patients, 25%). The cohort consisted of 119 patients (68%) with idiopathic VA, 31 (18%) with ischemic (ICM), and 26 (15%) with dilated cardiomyopathy (DCM). VA recurrence was observed in 69 patients (39%, mean age 51.71 ± 19.91 years, 23% female) during a follow-up period of 5.48 years (first quartile 770.50 days, second quartile 1101.50 days, third quartile 1615.50 days). Left ventricular ejection fraction &lt;40% lead to a significantly increased risk for VA (p = 0.031*). Multivariate analyses found DCM to be an independent predictor (IP) for VA recurrence (p &lt; 0.001*, hazard ratio (HR) 3.74, confidence interval (CI) 1.58-8.88). ICM resulted in a lower increase in VA recurrence (p = 0.221, HR 1.49, CI 0.79-2.81). Class I/III/IV antiarrhythmic drug therapy (AADs) was also identified as IP for recurrence (p = 0.030*, HR 2.48, CI 1.11-5.68). A total of 16 patients (9%) died within the observational period. RMN-guided ablation of VA lead to acceptable long-term results. An impaired LV function, DCM, and AADs were associated with a significant risk for VA recurrence. Personalized paths are needed to improve efficacy and outcome.</pubmed_abstract><journal>Journal of clinical medicine</journal><pagination>4695</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8540658</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Long-Term Efficacy and Impact on Mortality of Remote Magnetic Navigation Guided Catheter Ablation of Ventricular Arrhythmias.</pubmed_title><pmcid>PMC8540658</pmcid><pubmed_authors>Niemann S</pubmed_authors><pubmed_authors>Steinhauer P</pubmed_authors><pubmed_authors>Braun M</pubmed_authors><pubmed_authors>Khalaph M</pubmed_authors><pubmed_authors>Sohns C</pubmed_authors><pubmed_authors>Molatta S</pubmed_authors><pubmed_authors>Guckel D</pubmed_authors><pubmed_authors>Imnadze G</pubmed_authors><pubmed_authors>Sciacca V</pubmed_authors><pubmed_authors>Ditzhaus M</pubmed_authors><pubmed_authors>Fink T</pubmed_authors><pubmed_authors>Nolker G</pubmed_authors><pubmed_authors>Bergau L</pubmed_authors><pubmed_authors>Sommer P</pubmed_authors><pubmed_authors>El Hamriti M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Long-Term Efficacy and Impact on Mortality of Remote Magnetic Navigation Guided Catheter Ablation of Ventricular Arrhythmias.</name><description>Remote magnetic navigation (RMN) facilitates ventricular arrhythmia (VA) ablation. This study aimed to evaluate the long-term efficacy of RMN-guided ablation for ventricular tachycardia (VT) and premature ventricular contractions (PVC). A total of 176 consecutive patients (mean age 53.23 ± 17.55 years, 37% female) underwent VA ablation for PVC (132 patients, 75%) or VT (44 patients, 25%). The cohort consisted of 119 patients (68%) with idiopathic VA, 31 (18%) with ischemic (ICM), and 26 (15%) with dilated cardiomyopathy (DCM). VA recurrence was observed in 69 patients (39%, mean age 51.71 ± 19.91 years, 23% female) during a follow-up period of 5.48 years (first quartile 770.50 days, second quartile 1101.50 days, third quartile 1615.50 days). Left ventricular ejection fraction &lt;40% lead to a significantly increased risk for VA (p = 0.031*). Multivariate analyses found DCM to be an independent predictor (IP) for VA recurrence (p &lt; 0.001*, hazard ratio (HR) 3.74, confidence interval (CI) 1.58-8.88). ICM resulted in a lower increase in VA recurrence (p = 0.221, HR 1.49, CI 0.79-2.81). Class I/III/IV antiarrhythmic drug therapy (AADs) was also identified as IP for recurrence (p = 0.030*, HR 2.48, CI 1.11-5.68). A total of 16 patients (9%) died within the observational period. RMN-guided ablation of VA lead to acceptable long-term results. An impaired LV function, DCM, and AADs were associated with a significant risk for VA recurrence. Personalized paths are needed to improve efficacy and outcome.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Oct</publication><modification>2025-04-04T07:20:12.579Z</modification><creation>2025-04-04T07:20:12.579Z</creation></dates><accession>S-EPMC8540658</accession><cross_references><pubmed>34682822</pubmed><doi>10.3390/jcm10204695</doi></cross_references></HashMap>